KOD
Kodiak Sciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$35.36
−2.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | 26.7M | 25.9M | 11.0M |
| Gross Profit | — | — | (26.7M) | (25.9M) | (11.0M) |
| Operating Expenses | |||||
| R&D Expense | 200.6M | 182.4M | 126.1M | 206.3M | 267.6M |
| SG&A Expense | 45.8M | 52.0M | 34.0M | 71.0M | 62.8M |
| General & Admin Expense | 45.8M | 52.0M | — | 71.0M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | (25.9M) | — |
| Total Operating Expenses | 246.4M | 234.4M | 160.1M | 251.4M | 330.4M |
| Cost and Expenses | 246.4M | 234.4M | 186.8M | 277.3M | 341.4M |
| Operating Income (EBIT) | (246.4M) | (234.4M) | (186.8M) | (277.3M) | (341.4M) |
| Non-Operating | |||||
| Interest Income | 4.6M | 4.5M | 11.1M | 16.7M | 7.1M |
| Interest Expense | — | — | — | 13.0K | 18.0K |
| Net Interest Income | 4.6M | 4.5M | 11.1M | 16.7M | 7.1M |
| Other Non-Op Income/Expense | 4.4M | 4.4M | 10.6M | 16.8M | 7.6M |
| Non-Operating Income (excl Interest) | (7.0M) | (4.4M) | (10.6M) | (16.8M) | (7.6M) |
| EBT (Pre-Tax Income) | (242.0M) | (230.0M) | (176.2M) | (260.5M) | (333.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (242.0M) | (230.0M) | (176.2M) | (260.5M) | (333.8M) |
| Earnings from Cont. Ops | (242.0M) | (230.0M) | (176.2M) | (260.5M) | (333.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (242.0M) | (230.0M) | (176.2M) | (260.5M) | (333.8M) |
| Per Share | |||||
| Basic EPS | ($4.19) | ($4.32) | ($3.35) | ($4.97) | ($6.39) |
| Diluted EPS | ($4.19) | ($4.32) | ($3.35) | ($4.97) | ($6.39) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 62.6M | 53.2M | 52.6M | 52.4M | 52.2M |
| Diluted Shares Outstanding | 62.6M | 53.2M | 52.6M | 52.4M | 52.2M |
| Profitability Metrics | |||||
| EBITDA | (220.0M) | (203.6M) | (149.5M) | (234.5M) | (322.8M) |
| D&A | 19.4M | 26.3M | 26.7M | 25.9M | 11.0M |
| EBIT | (239.4M) | (230.0M) | (176.2M) | (260.5M) | (333.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026